|
| 36975214 | The Natural Stilbenoid (-)-Hopeaphenol Inhibits HIV Transcription by Targeting Both PKC and NF-κB Signaling and Cyclin-Dependent Kinase 9. | Antimicrob Agents Chemother | 2023 |
| 35979886 | "I Know That I Was a Part of Making a Difference": Participant Motivations for Joining a Cure-Directed HIV Trial with an Analytical Treatment Interruption. | AIDS Res Hum Retroviruses | 2023 |
| 37837376 | Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States. | HIV Res Clin Pract | 2023 |
| 37463049 | The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy. | J Clin Invest | 2023 |
| 37070542 | Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons. | AIDS | 2023 |
| 36792544 | Immune response to ART initiation in advanced HIV infection. | | 2023 |
| 36854720 | Stenotrophomonas maltophilia pneumonia in critical COVID-19 patients. | Sci Rep | 2023 |
| 35348047 | "We are looking at the future right now": community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States. | HIV Res Clin Pract | 2022 |
| 35657826 | Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). | PLoS One | 2022 |
| 35522580 | Ansellone J, a Potent <i>in Vitro</i> and <i>ex Vivo</i> HIV-1 Latency Reversal Agent Isolated from a <i>Phorbas</i> sp. Marine Sponge. | J Nat Prod | 2022 |
| 35968737 | Participant experiences using novel home-based blood collection device for viral load testing in HIV cure trials with analytical treatment interruptions | HIV Res Clin Pract | 2022 |
| 35891417 | HPLC-Based Purification and Isolation of Potent Anti-HIV and Latency Reversing Daphnane Diterpenes from the Medicinal Plant <i>Gnidia sericocephala</i> (<i>Thymelaeaceae</i>). | Viruses | 2022 |
| 35730977 | Inhibition of a Chromatin and Transcription Modulator, SLTM, Increases HIV-1 Reactivation Identified by a CRISPR Inhibition Screen. | J Virol | 2022 |
| 35923143 | Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV. | AIDS Research and Human Retroviruses | 2022 |
| 35916053 | Methadone use is associated with increased levels of sCD14, immune activation, and inflammation during suppressed HIV infection. | J Leukoc Biol | 2022 |
| 35320704 | Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic TÂ cell clones. | Immunity | 2022 |
| 35207719 | Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United States. | J Pers Med | 2022 |
| 35169590 | Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens. | Open Forum Infectious Diseases | 2022 |
| 34609897 | Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort. | AIDS Patient Care and STDs | 2021 |
| 33577894 | Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency. | Biochem Pharmacol | 2021 |
| 33527127 | Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy. | Clin Infect Dis | 2021 |
| 34002626 | Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States. | AIDS Research and Human Retroviruses | 2021 |
| 33622719 | Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption. | mBio | 2021 |
| 34049356 | Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption. | AIDS | 2021 |
| 33838004 | Weight gain before and after switch from TDF to TAF in a U.S. cohort study. | Journal of the International AIDS Society | 2021 |
| 34188039 | Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV. | Nat Commun | 2021 |
| 34086344 | Identification of the predominant human NK cell effector subset mediating ADCC against HIV-infected targets coated with BNAbs or plasma from PLWH. | Eur J Immunol | 2021 |
| 33710017 | To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment. | AIDS | 2021 |
| 33048874 | Incident type 2 diabetes mellitus after initiation of common HIV antiretroviral drugs. | AIDS | 2021 |
| 33180174 | No differences in delay discounting between smokers with and without HIV. | Psychopharmacology (Berl) | 2021 |
| 33323024 | Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial. | AIDS Res Hum Retroviruses | 2021 |
| 32895573 | Recommendations for measuring HIV reservoir size in cure-directed clinical trials. | Nat Med | 2020 |
| 32265700 | Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide. | Front Pharmacol | 2020 |
| 32053682 | Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. | PLoS One | 2020 |
| 31985887 | Validation of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) chronic kidney disease risk score in HIV-infected patients in the USA. | HIV Medicine | 2020 |
| 31972605 | Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. | AIDS | 2020 |
| 33211670 | Assessing bias introduced in estimated glomerular filtration rate by the inhibition of creatinine tubular secretion from common antiretrovirals. | Antiviral Therapy | 2020 |
| 32827942 | Interferon-α alters host glycosylation machinery during treated HIV infection. | EBioMedicine | 2020 |
| 32711800 | Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. | Lancet, The | 2020 |
| 33239444 | Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. | Proc Natl Acad Sci U S A | 2020 |
| 33343858 | Antiretroviral therapy and liver disorders in the OPERA cohort. | Therapeutic Advances in Drug Safety | 2020 |
| 32788215 | The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal. | J Biol Chem | 2020 |
| 32675559 | Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individuals. | AIDS | 2020 |
| 31253727 | NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects. | J Immunol | 2019 |
| 30399039 | Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and Research. | J Acquir Immune Defic Syndr | 2019 |
| 30414209 | Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure. | Pharmacotherapy | 2019 |
| 30651100 | HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA observational database: a cohort study. | AIDS Research and Therapy | 2019 |
| 31082665 | Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV. | Drug Alcohol Depend | 2019 |
| 30946162 | Differences in the rate of nicotine metabolism among smokers with and without HIV. | AIDS | 2019 |
| 29633346 | Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy. | J Leukoc Biol | 2018 |